{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:12:24Z","timestamp":1785186744161,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bulcan.2020.05.013","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T02:58:23Z","timestamp":1598583503000},"page":"861-866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Imatinib dans le traitement de la leuc\u00e9mie my\u00e9loide chronique au Maroc"],"prefix":"10.1016","volume":"107","author":[{"given":"Mariem","family":"Dakkoune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Qachouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Zoukal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Hassoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisrine","family":"Khoubila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Cherkaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Lamchahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rachid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdellah","family":"Madani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Quessar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement 4","key":"10.1016\/j.bulcan.2020.05.013_bib0085","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2020.05.013_bib0090","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018\u00a0update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2020.05.013_bib0095","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminhematol.2010.07.001","article-title":"Chronic myeloid leukemia: a historical perspective","volume":"47","author":"Goldman","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bulcan.2020.05.013_bib0100","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2020.05.013_bib0105","first-page":"22","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","author":"Abboud","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2020.05.013_bib0110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"10.1016\/j.bulcan.2020.05.013_bib0115","first-page":"229","article-title":"Molecular monitoring of Tunisian patients with chronic myeloid leukemia","volume":"95","author":"Menif","year":"2017","journal-title":"Tunis Med"},{"key":"10.1016\/j.bulcan.2020.05.013_bib0120","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the international registry for chronic myeloid leukemia in children and adolescents","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2020.05.013_bib0125","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00277-017-3224-2","article-title":"Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience)","volume":"97","author":"Ben Lakhal","year":"2018","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.bulcan.2020.05.013_bib0130","first-page":"128","article-title":"Leuc\u00e9mie my\u00e9lo\u00efde chronique\u00a0: des r\u00e9ponses et des questions","volume":"19","author":"Ledoux","year":"2013","journal-title":"Med Therap"},{"issue":"23","key":"10.1016\/j.bulcan.2020.05.013_bib0135","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five year follow of patients receiving imatinib for CML","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2020.05.013_bib0140","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic\u00a0\u2013\u00a0phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int J Hematol"},{"issue":"10","key":"10.1016\/j.bulcan.2020.05.013_bib0145","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00277-016-2745-4","article-title":"Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting","volume":"95","author":"Faye","year":"2016","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.bulcan.2020.05.013_bib0150","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.bulcan.2020.05.013_bib0155","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bulcan.2020.05.013_bib0080","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic myeloid leukemia","volume":"348","author":"O\u2019Brien SG1","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120303143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455120303143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:33:24Z","timestamp":1757792004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455120303143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0007455120303143"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.05.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib dans le traitement de la leuc\u00e9mie my\u00e9loide chronique au Maroc","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}